129167-72-2

Basic information

• Product Name: 3-bromo-4-t-butylbenzyl alcohol
• Synonyms: 3-bromo-4-t-butylbenzyl alcohol
• CAS NO: 129167-72-2
• Molecular Weight: 243.143
• Mol File: 129167-72-2.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 3-bromo-4-t-butylbenzyl alcohol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-bromo-4-t-butylbenzyl alcohol(129167-72-2)
• EPA Substance Registry System: 3-bromo-4-t-butylbenzyl alcohol(129167-72-2)

Safety Data

• Hazardous Substances Data: 129167-72-2(Hazardous Substances Data)

Upstream product

• 14034-08-3 methyl 3-bromo-4-(tert-butyl)benzoate 
• 38473-89-1 3-bromo-4-(tert-butyl)benzoic acid 
• 98-73-7 4-(1,1-dimethylethyl)benzoic acid 

Downstream Products

• 129167-75-5 3,4-di-t-butylbenzoic acid 
• 103391-77-1 3,4-di-t-butyltoluene 
• 129167-74-4 2-bromo-1-(tert-butyl)-4-methylbenzene 
• 98-51-1 4-tert-butyltoluene 
• 88-60-8 2-tert-Butyl-5-methylphenol 
• 129167-73-3 3-bromo-4-(tert-butyl)benzaldehyde 

Relevant articles and documents

TRIAZOLONE COMPOUNDS AND USES THEREOF

The invention disclosed herein is directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist.